Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Akeem SantosDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0009-0002-3507-1602
Zeneng WangDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0002-6455-8228
Rashmi BhartiDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0002-7612-7695
Goutam DeyDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0002-8210-3219
Naseer SangwanDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0002-2407-769X
William BaldwinDepartment of Inflammation & Immunity, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0002-7271-1827
Ajay ZalavadiaImaging Core, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0002-4468-3865
Alex MyersDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0009-0003-0895-7894
Olivia G HuffmanDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Justin D LathiaDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0003-3168-7290
Stanley L HazenDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0001-7124-6639
Ofer ReizesDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0003-0075-6871
Mohammed DwidarDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0003-1366-0393
Funding
TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3M
Project 3: Microbiota generated aryl sulfates and secondary bile acids in cardiometabolic diseaseP01HL147823 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MICHAEL ANDREW FISCHBACH · 2019 to 2026
$17.0M
Gut Flora Metabolism of Dietary Phosphatidylcholine and CVDR01HL103866 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI HAZEN, STANLEY L · 2010 to 2023
$10.8M
Synthetic biology tools and strategies to streamline the sensing and responding to disease cues in engineered theragnostic bacteria.R35GM156762 · NIGMS · CLEVELAND CLINIC LERNER COM-CWRU · PI Mohammed Dwidar · 2025 to 2026
$805k
Cancer-specific metabolites as cues to engineer and target anti-tumor therapeutic bacteriaR21CA267711 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI DWIDAR, MOHAMMED · 2022 to 2023
Widespread application of bacterial-based cancer therapy is limited because of the need to increase therapeutic bacteria specificity to the tumor to improve treatment safety and efficacy. Here, we harness the altered tumor metabolism and specifically elevated kynurenine accumulation to target engineered bacteria to the cancer site. We cloned and leveraged kynurenine-responsive transcriptional regulator (KynR) with its cognate promoter in
Indexed as
Breast NeoplasmsNeoplasmsOvarian NeoplasmsSalmonella entericaAnimalsCell Line, TumorEscherichia coliFemaleHumansKynurenineMiceKynurenine
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Leveraging dysregulated tumor metabolism for targeting anticancer bacteria. · full record | OpenQuestion